Malignant mesothelioma

Common Name(s)

Malignant mesothelioma

Malignant mesothelioma is an aggressive neoplasm of the serosal lining of the chest etiologically linked to asbestos. It is diagnosed in approximately 2,000 to 3,000 individuals annually in the United States, most of whom die within 2 years of diagnosis (summary by {6:Bott et al., 2011}). See also {614327} for a tumor predisposition syndrome that may contribute to the development of malignant mesothelioma upon asbestos exposure and is caused by germline mutation in the BAP1 gene ({603089}) on chromosome 3p21.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Malignant mesothelioma" for support, advocacy or research.

Logo
Mesothelioma Applied Research Foundation

The Mesothelioma Applied Research Foundation is the nonprofit collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. We believe in a cure for meso. Given the human toll of suffering the disease causes, the compassion and energy of the meso community, the moral, legal and economic aspects of asbestos, and the benefits of meso research to cancer research generally, we believe that the resources to accomplish this cure are available and must be mobilized. We seek to marshal and utilize these resources responsibly, as effectively as possible, with financial transparency and by adhering to health policy guidelines that foster ethical clinical and administrative practices, and ethical decision making to: • Offer hope and support to patients and families by educating them on the disease, helping them to obtain the most up-to-date information on treatment options and to connect with meso tr

Last Updated: 1 Mar 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Malignant mesothelioma" for support, advocacy or research.

Logo
Mesothelioma Applied Research Foundation

The Mesothelioma Applied Research Foundation is the nonprofit collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. We believe in a cure for meso. Given the human toll of suffering the disease causes, the compassion and energy of the meso community, the moral, legal and economic aspects of asbestos, and the benefits of meso research to cancer research generally, we believe that the resources to accomplish this cure are available and must be mobilized. We seek to marshal and utilize these resources responsibly, as effectively as possible, with financial transparency and by adhering to health policy guidelines that foster ethical clinical and administrative practices, and ethical decision making to: • Offer hope and support to patients and families by educating them on the disease, helping them to obtain the most up-to-date information on treatment options and to connect with meso tr

http://www.curemeso.org

Last Updated: 1 Mar 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Malignant mesothelioma" returned 991 free, full-text research articles on human participants. First 3 results:

Pretreatment elevated serum lactate dehydrogenase as a significant prognostic factor in malignant mesothelioma: A meta-analysis.
 

Author(s): Yi Zhuo, Lanying Lin, Shushan Wei, Mingwei Zhang

Journal: Medicine (Baltimore). 2016 Dec;95(52):e5706.

 

Lactate dehydrogenase (LDH) as a hypoxia-regulator plays a vital role in alternative metabolic pathways of cancer cells. Numerous studies have assessed the prognostic value of elevated pretreatment LDH in malignant mesothelioma (MM). However, the results have been largely inconsistent. ...

Last Updated: 29 Dec 2016

Go To URL
Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report.
 

Author(s): Irene Vanni, Simona Coco, Silvia Bonfiglio, Davide Cittaro, Carlo Genova, Federica Biello, Marco Mora, Valeria Rossella, Maria Giovanna Dal Bello, Anna Truini, Barbara Banelli, Dejan Lazarevic, Angela Alama, Erika Rijavec, Giulia Barletta, Francesco Grossi

Journal: Medicine (Baltimore). 2016 Nov;95(48):e5447.

 

The presence of multiple primary tumors (MPT) in a single patient has been identified with an increasing frequency. A critical issue is to establish if the second tumor represents an independent primary cancer or a metastasis. Therefore, the assessment of MPT clonal origin might help ...

Last Updated: 30 Nov 2016

Go To URL
Intensity-modulated radiotherapy for relapsed malignant pleural mesothelioma.
 

Author(s): Corrado Spatola, Carmelo Militello, Alessandra Tocco, Vincenzo Salamone, Luigi Raffaele, Marcello Migliore, Antonio Pagana, Roberto Milazzotto, Ilenia Chillura, Stefano Pergolizzi, Giuseppe Privitera

Journal: Future Oncol. 2016 Dec;12(23s):67-71.

 

The use of novel radiotherapy techniques is widely increasing, allowing clinicians to treat diseases that were previously difficult to treat with radiation therapy. Malignant pleural mesothelioma is a clear example of this clinical challenge. We describe our first experience with ...

Last Updated: 21 Sep 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Malignant mesothelioma" returned 101 free, full-text review articles on human participants. First 3 results:

[Drug carrier nanosystems in malignant pleural mesothelioma].
 

Author(s): Didem Turgut Coşan, Güntülü Ak, İlknur Dağ, Ahu Soyocak, Gökhan Dikmen, Aylin Dal, Hasan V Güneş, Muzaffer Metintaş

Journal: Tuberk Toraks. 2016 Mar;64(1):60-8.

 

Malignant pleural mesothelioma (MPM), the incidence increased with each passing day, is an important lethal disease due to the limited survive with available treatment methods and with the lack of a standard treatment. Response and survive rates of cytotoxic agents which is used in ...

Last Updated: 9 Jun 2016

Go To URL
Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
 

Author(s): Xu-Quan Jing, Lei Zhou, Xin-Dong Sun, Jin-Ming Yu, Xue Meng

Journal: Medicine (Baltimore). 2016 Apr;95(14):e3351.

 

Malignant pleural mesothelioma (MPM) is a lethal disease with poor prognosis. The combination of cisplatin and pemetrexed has been confirmed as the standard of care for nonoperable MPM. Data have shown that the adoption of pemetrexed maintenance therapy (PMT) following first-line ...

Last Updated: 9 Apr 2016

Go To URL
A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience.
 

Author(s): Isabelle Opitz, Martina Friess, Peter Kestenholz, Didier Schneiter, Thomas Frauenfelder, Thi Dan Linh Nguyen-Kim, Burkhardt Seifert, Mir Alireza Hoda, Walter Klepetko, Rolf A Stahel, Walter Weder

Journal: J Thorac Oncol. 2015 Nov;10(11):1634-41.

 

Treatment of malignant pleural mesothelioma (MPM) remains a clinical challenge. The aim of this study was to identify selection factors for allocation of MPM patients to multimodal therapy based on survival data from 12 years of experience.

Last Updated: 6 Nov 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
 

Status: Not yet recruiting

Condition Summary: Mesothelioma

 

Last Updated: 28 Mar 2016

Go to URL
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
 

Status: Recruiting

Condition Summary: Mesothelioma

 

Last Updated: 1 Feb 2017

Go to URL
A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)
 

Status: Recruiting

Condition Summary: Pleural Mesothelioma; Peritoneal Mesothelioma

 

Last Updated: 26 Oct 2015

Go to URL